http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017184875-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_57c0c8785a2ce0017c65850330ce1d7e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C59-265 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D457-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D457-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2017-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6fc749724ece7854f87998eb320229a |
| publicationDate | 2017-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2017184875-A1 |
| titleOfInvention | Composition and method for treating metabolic disorders |
| abstract | Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3697418-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11510921-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11560375-B2 |
| priorityDate | 2016-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 209.